Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcoma

Cancer

Volumn 117, Issue 21, 2011, Pages 4925-4938

  Yang, Jilong ^a,b   Yang, Da ^b   Sun, Yan ^a   Sun, Baocun ^a   Wang, Guowen ^a   Trent, Jonathan C ^b   Araujo, Dejka M ^b   Chen, Kexin ^a   Zhang, Wei ^b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

fluorescent in situ hybridization; gene amplification; microarray based comparative genomic hybridization; osteosarcoma; vascular endothelial growth factor A

Indexed keywords

VASCULOTROPIN;

ADOLESCENT; ADULT; ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENRICHMENT CULTURE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION; GENETIC DATABASE; GENETIC GAIN; GENETIC SCREENING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; ONCOGENE; OSTEOSARCOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; VEGFA GENE;

ADOLESCENT; ADULT; BONE NEOPLASMS; DISEASE-FREE SURVIVAL; GENE AMPLIFICATION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; NEOVASCULARIZATION, PATHOLOGIC; OSTEOSARCOMA; PROGNOSIS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80053237717     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26116     Document Type: Article

References (39)

1. Unni KK, Inwards CY,. Dahlin's Bone Tumours. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2010.
2. Yang J, Cogdell D, Yang D, et al. Deletion of the WWOX gene and frequent loss of its protein expression in human osteosarcoma. Cancer Lett. 2010; 291: 31-38.
3. Quan GM, Choong PF,. Anti-angiogenic therapy for osteosarcoma. Cancer Metastasis Rev. 2006; 25: 707-713. (Pubitemid 46071873)
4. Dvorak HF,. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol. 2002; 20: 4368-4380. (Pubitemid 35266299)
5. Zangari M, Anaissie E, Stopeck A, et al. Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. Clin Cancer Res. 2004; 10 (1 pt 1): 88-95. (Pubitemid 38114166)
6. Budde A, Schneiderhan-Marra N, Petersen G, Brune B,. Retinoblastoma susceptibility gene product pRB activates hypoxia-inducible factor-1 (HIF-1). Oncogene. 2005; 24: 1802-1808. (Pubitemid 40461136)
7. Man TK, Lu XY, Jaeweon K, et al. Genome-wide array comparative genomic hybridization analysis reveals distinct amplifications in osteosarcoma [serial online]. BMC Cancer. 2004; 4: 45.
8. Fechter A, Buettel I, Kuehnel E, Schwab M, Savelyeva L,. Cloning of genetically tagged chromosome break sequences reveals new fragile sites at 6p21 and 13q22. Int J Cancer. 2007; 120: 2359-2367. (Pubitemid 46642122)
9. Pasic I, Shlien A, Durbin AD, et al. Recurrent focal copy-number changes and loss of heterozygosity implicate 2 noncoding RNAs and 1 tumor suppressor gene at chromosome 3q13.31 in osteosarcoma. Cancer Res. 2010; 70: 160-171.
10. Squire JA, Pei J, Marrano P, et al. High-resolution mapping of amplifications and deletions in pediatric osteosarcoma by use of CGH analysis of cDNA microarrays. Genes Chromosomes Cancer. 2003; 38: 215-225. (Pubitemid 37259638)
11. Meyers PA, Heller G, Healey J, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol. 1992; 10: 5-15.
12. Boussen H, Mezzi F, Gamoudi A, et al. [Primary chemotherapy with the Rosen T10 protocol before conservative surgery in limb primitive osteosarcomas: results about 56 cases]. Bull Cancer. 2000; 87: 183-188. (Pubitemid 30167159)
13. Olshen AB, Venkatraman ES, Lucito R, Wigler M,. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics. 2004; 5: 557-572. (Pubitemid 41180205)
14. Van Wieringen WN, Van De Wiel MA, Ylstra B,. Weighted clustering of called array CGH data. Biostatistics. 2008; 9: 484-500. (Pubitemid 351882087)
15. Kresse SH, Ohnstad HO, Paulsen EB, et al. LSAMP, a novel candidate tumor suppressor gene in human osteosarcomas, identified by array comparative genomic hybridization. Genes Chromosomes Cancer. 2009; 48: 679-693.
16. Summersgill B, Clark J, Shipley J,. Fluorescence and chromogenic in situ hybridization to detect genetic aberrations in formalin-fixed paraffin embedded material, including tissue microarrays. Nat Protoc. 2008; 3: 220-234. (Pubitemid 351266506)
17. Wang WL, Mayordomo E, Zhang W, et al. Detection and characterization of EWSR1/ATF1 and EWSR1/CREB1 chimeric transcripts in clear cell sarcoma (melanoma of soft parts). Mod Pathol. 2009; 22: 1201-1209.
18. Freeman SS, Allen SW, Ganti R, et al. Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors. Cancer. 2008; 113: 1453-1461.
19. Kersting C, Tidow N, Schmidt H, et al. Gene dosage PCR and fluorescence in situ hybridization reveal low frequency of egfr amplifications despite protein overexpression in invasive breast carcinoma. Lab Invest. 2004; 84: 582-587. (Pubitemid 38858467)
20. Ek ET, Ojaimi J, Kitagawa Y, Choong PF,. Does the degree of intratumoural microvessel density and VEGF expression have prognostic significance in osteosarcoma? Oncol Rep. 2006; 16: 17-23.
21. Abdel-Rahman MH, Craig EL, Davidorf FH, Eng C,. Expression of vascular endothelial growth factor in uveal melanoma is independent of 6p21-region copy number. Clin Cancer Res. 2005; 11: 73-78. (Pubitemid 40075780)
22. DuBois S, Demetri G,. Markers of angiogenesis and clinical features in patients with sarcoma. Cancer. 2007; 109: 813-819. (Pubitemid 46333523)
23. Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF,. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol. 2009; 27: 1323-1333.
24. Ferrari S, Smeland S, Mercuri M, et al. Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol. 2005; 23: 8845-8852. (Pubitemid 46211531)
25. Kreuter M, Bieker R, Bielack SS, et al. Prognostic relevance of increased angiogenesis in osteosarcoma. Clin Cancer Res. 2004; 10: 8531-8537. (Pubitemid 40053420)
26. Mizobuchi H, Garcia-Castellano JM, Philip S, Healey JH, Gorlick R,. Hypoxia markers in human osteosarcoma: an exploratory study. Clin Orthop Relat Res. 2008; 466: 2052-2059.
27. Rennel E, Waine E, Guan H, et al. The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice. Br J Cancer. 2008; 98: 1250-1257. (Pubitemid 351481687)
28. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007; 25: 118-145. (Pubitemid 350003059)
29. Arena V, Pennacchia I, Carbone A, Capelli A,. Fluorescent in situ hybridization for human epidermal growth factor receptor 2 assessment in breast cancer: is it applicable as a primary test [letter; serial online]? J Clin Oncol. 2009; 27: e8; author reply e9-e10.
30. Arena V, Pennacchia I, Monego G, Carbone A, Capelli A,. Fluorescent in situ hybridization as a primary test for HER2 status in breast cancer: controversies [letter; serial online]. J Clin Oncol. 2010; 28: e83-e84; author reply e85-e88.
31. Hicklin DJ, Ellis LM,. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005; 23: 1011-1027. (Pubitemid 46202320)
32. Du R, Lu KV, Petritsch C, et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell. 2008; 13: 206-220. (Pubitemid 351318372)
33. Suzuki S, Dobashi Y, Sakurai H, Nishikawa K, Hanawa M, Ooi A,. Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas. An immunohistochemical and fluorescence in situ hybridization study. Cancer. 2005; 103: 1265-1273. (Pubitemid 40328099)
34. Konishi T, Huang CL, Adachi M, et al. The K-ras gene regulates vascular endothelial growth factor gene expression in non-small cell lung cancers. Int J Oncol. 2000; 16: 501-511.
35. O'Day K, Gorlick R,. Novel therapeutic agents for osteosarcoma. Expert Rev Anticancer Ther. 2009; 9: 511-523.
36. Humar R, Kiefer FN, Berns H, Resink TJ, Battegay EJ,. Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. FASEB J. 2002; 16: 771-780. (Pubitemid 34615125)
37. Wan X, Mendoza A, Khanna C, Helman LJ,. Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res. 2005; 65: 2406-2411. (Pubitemid 40490152)
38. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med. 2002; 8: 128-135. (Pubitemid 34155123)
39. Houghton PJ, Morton CL, Kolb EA, et al. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008; 50: 799-805. (Pubitemid 351354788)